

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 15**

---

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION  
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934  
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTION 13 AND 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number: 001-39488

---

**Apexigen, Inc.**

(Exact name of registrant as specified in its charter)

---

900 Industrial Road, Suite C  
San Carlos, CA 94070  
(650) 931-6236

(Address, including, zip code and telephone number, including area code, of registrant's principal executive offices)

**Common Stock, par value \$0.0001 per share**  
**Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of \$11.50 per share**  
(Title of each class of securities covered by this Form)

**None**  
(Title of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

---

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input type="checkbox"/>
Rule 15d-22(b)	<input type="checkbox"/>

Approximate number of holders of record as of the certification or notice date: One.\*

\* On August 23, 2023, pursuant to that certain Agreement and Plan of Merger, dated as of May 23, 2023, by and among Pyxis Oncology, Inc., a Delaware corporation ("Pyxis Oncology"), Apexigen, Inc., a Delaware corporation ("Apexigen"), and Ascent Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of Pyxis Oncology ("Merger Sub"), Merger Sub merged with and into Apexigen, with Apexigen surviving as a wholly-owned subsidiary of Pyxis Oncology.

Pursuant to the requirements of the Securities Exchange Act of 1934, Apexigen, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: September 5, 2023

**Apexigen, Inc.**

By: /s/ Pam Connealy  
Pam Connealy  
Chief Financial Officer and Chief Operating Officer

---

---